Trial Profile
A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of the Salmeterol/Fluticasone combination product (50/500mg strength) twice daily with Salmeterol 50mg twice daily alone and Fluticasone Propionate 500mg twice daily alone, all delivered via the Diskus/Accuhaler inhaler, in the treatment of patients with chronic obstructive pulmonary disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms TRISTAN
- Sponsors GlaxoSmithKline; GSK
- 19 May 2015 Post-hoc analysis results from this and two other trials (SCO40036 and SCO30002) presented at the American Thoracic Society (ATS) meeting 2015, according to a GlaxoSmithKline media release.
- 05 Nov 2010 New trial record.